J.P.
H.C.
Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.
Cowen places more importance on ORR strength than reduction in OS for IMMU’s prospects for a green light.
BMO stays on the sidelines as VRX still faces headwinds, but praises key “headway” in growth.
Unfavorable Teva risk/reward and steep valuation keeps Oppenheimer on the sidelines.
One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
Though investor sentiment has turned positive on VRX after 3Q earnings, Wells Fargo makes a bearish case.
Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.
Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.
